A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
Launched by HIBERCELL, INC. · Jan 29, 2024
Trial Information
Current as of June 18, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment combination of HC-7366 and belzutifan (also known as WELIREG™) for patients with a type of kidney cancer called renal cell carcinoma (RCC). Specifically, the trial aims to find out the safest and most effective dose of HC-7366 when used together with belzutifan in patients whose cancer is advanced or cannot be surgically removed. About 80 patients will participate in this study, which will take place at multiple centers, and will include different groups of patients based on their treatment needs.
To be eligible for this trial, participants must be at least 18 years old and have a diagnosis of locally advanced or metastatic RCC that mostly has a clear cell component. This means the cancer has spread beyond the kidney or cannot be completely removed through surgery. Those who join the trial can expect to receive careful monitoring and support as they participate in this important research aimed at improving treatment options for kidney cancer.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Has diagnosis of locally advanced (inoperable) or metastatic RCC with a predominant clear cell component
- • Be age 18 years or older (male or female) at the time of consent
About Hibercell, Inc.
Hibercell, Inc. is an innovative biopharmaceutical company focused on developing breakthrough therapies for patients with cancer and other serious diseases. Leveraging advanced scientific research and cutting-edge technology, Hibercell aims to harness the body's immune response to create effective treatments that target tumor cells. With a commitment to improving patient outcomes, the company is dedicated to conducting rigorous clinical trials and collaborating with leading research institutions to advance its pipeline of novel therapeutics, ultimately striving to enhance the quality of life for individuals facing challenging health conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Saint Louis, Missouri, United States
Los Angeles, California, United States
New York, New York, United States
Cleveland, Ohio, United States
Seattle, Washington, United States
Tucson, Arizona, United States
Dallas, Texas, United States
Cleveland, Ohio, United States
La Jolla, California, United States
Fairfax, Virginia, United States
Lone Tree, Colorado, United States
Portland, Oregon, United States
Madison, Wisconsin, United States
Saint Paul, Minnesota, United States
Nashville, Tennessee, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported